Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 64Colonic Neoplasms 19Rectal Neoplasms 12Esophageal Neoplasms 9Neoplasms 8Neoplasm Metastasis 8Cholangiocarcinoma 7Squamous Cell Carcinoma of Head and Neck 6Pancreatic Neoplasms 6Breast Neoplasms 6Colorectal Cancer Metastatic 5Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Head and Neck Neoplasms 4Ovarian Neoplasms 3Inflammatory Breast Neoplasms 3Carcinoma, Squamous Cell 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrence 2Prostatic Neoplasms 2Lung Neoplasms 2Glioma 2Gastrointestinal Neoplasms 2Carcinoma 2Biliary Tract Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1

Interventions

Panitumumab 1Gemcitabine 1Cystectomy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cone Dystrophy 3 × Panitumumab × Clear all
NCT01916109 2016-02-12

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
4 enrolled 6 charts
Genitourinary

Cone Dystrophy 3, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡